Delivery Order SPE2DR25D2005-SPE2DR26FE7K0
- Not listed
- The Defense Logistics Agency awarded a $1,899.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets, 28-count package) with a completion date of December 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion and extending through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $1,497.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for MYFEMBREE (a combined hormonal contraceptive tablet available in 40 mg, 1 mg, and 0.5 mg formulations, 28-count packaging) on December 4, 2025, with completion expected by December 5, 2025. This non-set-aside contract will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Myfembree (40 mg, 1 mg, and 0.5 mg tablets) in a quantity of 28 units. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $2,149.77 and is scheduled for completion by September 9, 2025. The contract represents a non-set-aside procurement, indicating AmerisourceBergen's competitive selection among qualified vendors....
- The Defense Logistics Agency awarded a $2,866.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 12, 2025, for the supply of Myfembree (40 mg, 1 mg, and 0.5 mg tablets in a 28-count package). This non-set-aside contract is scheduled for completion by December 15, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
- Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $2,970.00 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to provide MYFEMBREE 40/1/0.5 28S pharmaceutical products. This delivery order has a completion date of February 28, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA, valued up to $999,999,999.00 through December 31, 2025,...
- The Defense Logistics Agency awarded a delivery order valued at $2,991.21 to AmerisourceBergen Drug Corp for the supply of Myfembree (40 mg-1 mg-0.5 mg tablets, 28-count packages) on December 2, 2025, with completion scheduled for December 3, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,674.10 firm-fixed-price delivery order (SPE2DB20D2104|SPE2DB24FT99S) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to support military...
- The Defense Logistics Agency Troop Support Medical awarded a $1,530.93 delivery order to Amerisourcebergen Drug Corporation for the product "MYFEMBREE 40 MG-1 MG-0.5 MG TB 28S." The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is September 5-6, 2023. This firm fixed price order was placed under an indefinite-delivery/indefinite-quantity contract vehicle, though details of the underlying contract were not...
- The Defense Logistics Agency awarded a $3,364.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for pharmaceutical products on August 22, 2025, with an ultimate completion date of August 25, 2025. The delivery order covers Myfembree 40 mg–1 mg–0.5 mg tablets in a 28-day supply, a hormonal contraceptive medication. This is a non-set-aside competitive award issued against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $2,644.71 to AmerisourceBergen Drug Corp for the supply of Myfembree (a combination oral contraceptive containing 40 mg, 1 mg, and 0.5 mg tablets in a 28-tablet package). This firm fixed price delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-competitive award placed under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FE7K0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,618.42 to AmerisourceBergen Drug Corp for MYFEMBREE pharmaceutical products (40 mg, 1 mg, and 0.5 mg tablets, 28-count supply). This firm fixed-price delivery order, issued on November 24, 2025, represents a non-competitive set-aside award and is due for completion by November 25, 2025. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems and the Defense Health Agency. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains, from brand-name and generic medications to specialty treatments and medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 11/23/25 |